Cite
HARVARD Citation
Fan, Y. et al. (n.d.). 157PShort-term responders of non-small cell lung cancer patients to EGFR tyrosine kinase inhibitors display high prevalence of TP53 mutations and primary resistance mechanisms. Annals of oncology. p. . [Online].